Sugi Predict

Sugi Predict / Compounds / SCHEMBL565904

SCHEMBL565904

SCHEMBL565904

O=C(Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1)c1ccccc1

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P2RY6 Q15077 5/20 0.70
▸ P2RY14 Q15391 2/20 0.70
▸ NT5E P21589 1/20 0.70
▸ ABL1 P00519 1/20 0.63
▸ RIN1 Q13671 1/20 0.63
▸ POLB P06746 1/20 0.62
▸ LMNA P02545 2/20 0.60
▸ MTOR P42345 2/20 0.60
▸ THRB P10828 1/20 0.60
▸ MDM2 Q00987 1/20 0.60
▸ NCOA1 Q15788 1/20 0.60
▸ NCOA3 Q9Y6Q9 1/20 0.60
▸ MAPT P10636 1/20 0.54
▸ CDA P32320 1/20 0.54
▸ P2RY2 P41231 3/20 0.49
▸ P2RY4 P51582 3/20 0.49
▸ GMNN O75496 1/20 0.48
▸ ALDH1A1 P00352 1/20 0.48
▸ TP53 P04637 1/20 0.48
▸ NFKB1 P19838 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18852530 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL7267465 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL27878674 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL565905 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL14853856 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL16805383 1.00 P2RY6 (0.70) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL7527325 0.99 P2RY6 (0.69) P2RY6P2RY14NT5EABL1RIN1
Phosphoric Acid SCHEMBL21465041 0.97 P2RY6 (0.72) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL9945548 0.93 P2RY6 (0.61) P2RY6P2RY14NT5EABL1RIN1
SCHEMBL432297 0.92 P2RY6 (0.61) P2RY6P2RY14NT5EABL1RIN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 921 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022123501-A1 PROTECTED DEOXYDIDEHYDRO-NUCLEOSIDES VICTORIA LINK LIMITED (NZ) 2022-06-16 — — WO claimed
US-20220048941-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES Janssen Biopharma, Inc. (US) 2022-02-17 — — US claimed
US-11180524-B2 Modified nucleoside phosphoramidites Janssen Biopharma, Inc. (US) 2021-11-23 — — US claimed
US-20200255468-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES Janssen Pharmaceuticals, Inc. 2020-08-13 — — US claimed
CN-111465610-A Modified nucleoside phosphoramidites 詹森生物制药有限公司 2020-07-28 — — CN claimed
EP-3681894-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES Janssen BioPharma, Inc. (US) 2020-07-22 — — EP claimed
WO-2019053659-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES ALIOS BIOPHARMA, INC. (US) 2019-03-21 — — WO claimed
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS INC (US) 2017-06-22 — — US claimed
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Modema Therapeutics, Inc. (US) 2017-05-18 — — US claimed
EP-3157573-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 — — EP claimed
EP-3157572-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2017-04-26 — — EP claimed
WO-2015196130-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 — — WO claimed
WO-2015196128-A2 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2015-12-23 — — WO claimed
EP-4746905-A1 RSV VACCINE Astrazeneca AB (SE) 2026-05-27 — — EP disclosed
WO-2026104647-A1 VACCINE ASTRAZENECA AB (SE) 2026-05-21 — — WO disclosed
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
EP-0215942-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD. SUMMERTON JAMES 1987-04-01 — — EP disclosed
WO-1986005519-A1 POLYNUCLEOTIDE ASSAY REAGENT AND METHOD SUMMERTON JAMES 1986-09-25 — — WO disclosed
WO-1986005518-A1 STEREOREGULAR POLYNUCLEOTIDE-BINDING POLYMERS SUMMERTON JAMES 1986-09-25 — — WO disclosed
US-4474948-A Benzazolides and their employment in phosphite ester oligonucleotide synthesis processes BIOSEARCH (US) 1984-10-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200255468-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES PNP, MTAP, NT5C3B P2RY6 89/4885P2RY14 178/4885NT5E 15/4885
US-20170175129-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 P2RY6 2112/4885P2RY14 2371/4885NT5E 67/4885
US-11180524-B2 Modified nucleoside phosphoramidites PNP, MTAP, NT5C3B P2RY6 89/4885P2RY14 178/4885NT5E 15/4885
US-20170136131-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF NSUN2, RNGTT, NSUN3 P2RY6 2112/4885P2RY14 2371/4885NT5E 67/4885
US-20220048941-A1 MODIFIED NUCLEOSIDE PHOSPHORAMIDITES PNP, TYMP, NSUN2 P2RY6 292/4885P2RY14 525/4885NT5E 241/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.